Blogs about: Recombinant
Featured Blog
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
-ELOCTATE™ Has Potential to Provide Long-Lasting Protection and Markedly Reduce Treatment Burden for Patients- WESTON, Mass.–(BUSINESS WIRE) – May 13, 2013 – Biogen Idec (NASDAQ: BII… more →
Bringing Generations Together
more word recombination
wrote 4 days ago: chk chk chk systems are online lets go call <blank> on gas and lunch /// no go clear mail and … more →
just word recombination
wrote 4 days ago: The .dot $dollarsign unto Uncertain times, desperate measures A time to sow & a time to reap The … more →
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
wrote 1 week ago: -ELOCTATE™ Has Potential to Provide Long-Lasting Protection and Markedly Reduce Treatment Burden for … more →
wrote 2 weeks ago: Pleiades (detail) from a star chart superimposed over a figure on Flickr. … more →
BIOGEN IDEC SUBMITS APPLICATION TO FDA FOR FIRST LONG-LASTING FACTOR VIII THERAPY FOR HEMOPHILIA A
wrote 2 months ago: Half-life of rFVIIIFc may enable prophylactic dosing once to twice weekly WESTON, Mass.–(BUSIN … more →
FDA Accepts Biogen Idec's Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B
wrote 2 months ago: WESTON, Mass.–(BUSINESS WIRE)–Mar. 4, 2013– Biogen Idec (NASDAQ: BIIB) announced t … more →
Marketing for Movie “Stoker” Produced Entirely from GIFs
wrote 2 months ago: GIFs – an acronym for “Graphics Interchange Format” – are short, animated computer images that have … more →
NEW PHASE 3 DATA REINFORCE LONG-LASTING PROTECTION FROM BLEEDING FOR PATIENTS WITH HEMOPHILIA A AND B
wrote 3 months ago: – Recombinant Fc fusion proteins show potential to transform care by providing long-lasting protecti … more →
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
wrote 3 months ago: STUDY: Factor VIII Products and Inhibitor Development in Severe Hemophilia A Samantha C. Gouw, M.D., … more →
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
wrote 4 months ago: DEERFIELD, Ill., January 24, 2013 – Baxter International Inc. (NYSE:BAX) announced today that … more →
Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B
wrote 4 months ago: WESTON, Mass.–(BUSINESS WIRE)–Jan. 4, 2013– Today Biogen Idec (NASDAQ: BIIB) annou … more →
Baxter to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A
wrote 4 months ago: DEERFIELD, Ill. – January 07, 2013 – (BUSINESS WIRE)–Baxter International Inc. (NY … more →
Baxter Presents Phase I/III Data Evaluating Safety and Efficacy of BAX 326, an Investigational Recombinant Factor IX for Hemophilia B
wrote 5 months ago: Study Shows More Than 40 Percent of Patients Experienced No Bleeds BAX 326 Granted Orphan-drug Desig … more →
Inspiration Biopharmaceuticals Highlights Positive Interim Data on its Two Lead Investigational Product Candidates
wrote 5 months ago: Recombinant Porcine FVIII (OBI-1) and Recombinant Factor IX (IB1001) Interim results suggest that O … more →
Baxter Presents Data on BAX 326, an Investigational Recombinant Factor IX for Hemophilia B
wrote 5 months ago: Baxter Presents Phase I/III Data Evaluating Safety and Efficacy of BAX 326, an Investigational Recom … more →
Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia
wrote 5 months ago: Published on November 28, 2012 at 5:05 AM on News Medical.net Bayer’s BAY 86-6150 is being inv … more →
OBI-1 has received Fast Track designation from FDA for acquired hemophilia A
wrote 6 months ago: Ipsen and Inspiration Biopharmaceuticals announce that OBI-1 has received Fast Track designation fro … more →
Pop Peacock
— 9 comments
wrote 6 months ago: Count me among the millions enamored of those strange birds Mother Nature garbs in the most exotic f … more →
Inspiration Biopharmaceuticals Files for Chapter 11 Protection in Order to Pursue a Broad Strategic Transaction
wrote 6 months ago: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Inspiration Biopharmaceuticals, Inc. (Inspiration), a b … more →
